Journal of Clinical Oncology
Articles in this Issue
Real-world impact of first immunotherapy infusion timing on outcomes in locally advanced non-small cell lung cancer.
8071 Background: Emerging evidence suggests that earlier time-of-day (ToD) infusion of immune checkpoint inhibitors (ICIs)...
Effect of statins on outcomes in renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective US cohort study.
e16553 Background: Immune checkpoint inhibitors (ICI) have transformed the treatment of renal cell carcinoma (RCC). Statin...
Perioperative chemotherapy in patients with grade 2 or 3 appendiceal cancer undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): A real-world data analysis.
e15522 Background: CRS with HIPEC is an established option for selected appendiceal cancers with peritoneal metastases. Cu...
TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC).
TPS1145 Background: Patients with HER2-positive metastatic breast cancer (HER2+ MBC) have limited therapeutic options afte...
A triage-forward outpatient diagnostic pathway for cancer evaluation: Early experiences from a Suspicion of Cancer clinic.
e23252 Background: The UCSD suspicion of cancer (SoC) clinic was developed to address the systemic reliance on inpatient c...
Risk of immune checkpoint inhibitor–related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease: A propensity score–matched analysis.
e20596 Background: Immune checkpoint inhibitors (ICIs) are standard therapy for non-small cell lung cancer (NSCLC) but can...
Intrathecal chemotherapy and central nervous system relapse in acute lymphoblastic leukemia.
e23063 Background: Central nervous system (CNS) involvement is a rare but devastating complication of acute lymphoblastic...
Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non–small cell lung cancer (NSCLC) study.
8057 Background: The NCI Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) study tes...
Association between mammary adipocyte diameter and survival outcomes in breast cancer patients.
e12720 Background: Obesity is associated with poorer breast cancer outcomes, yet body mass index (BMI) has limitations in...
Targeting metastatic sites with radiation and outcomes in high-risk pediatric rhabdomyosarcoma.
10002 Background: Outcomes for pediatric patients with metastatic rhabdomyosarcoma (RMS) remain poor despite therapy inten...
Contemporary real-world patterns of precision medicine in metastatic NSCLC.
e20665 Background: Precision medicine has become an essential part of lung cancer care over the last several years. The In...
Bowel function after sphincter-preserving treatment with neoadjuvant therapy for low rectal cancer.
3665 Background: Neoadjuvant therapy (NAT) is important for locally advanced rectal cancer, including neoadjuvant chemorad...
Territorial Oncology L’Aquila ASL1 Abruzzo, Italy: 11 years of experience in a complex organization integrating innovative outpatient oncologic treatment and care models.
e13582 Background: We report 11 years organization from 2014 and overall results of Oncology Territorial Care (OTC) Unit L...
NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.
TPS3685 Background: Patients with microsatellite-stable (MSS) colorectal cancer (CRC) who are ctDNA-positive following sur...
Association of <i>FBXW7</i> mutation with prolonged survival in microsatellite instability–high colorectal cancer treated with immune checkpoint blockade.
3657 Background: Colorectal cancer (CRC) remains a major cause of cancer-related mortality. Biomarkers of response to nove...
Role of cystine/glutamate transporter SLC7A11 in breast cancer brain metastatic cells.
e13123 Background: Brain metastases in patients with triple-negative breast cancer (TNBC) pose many challenges due to thei...
Multicenter phase Ib/II study of neoadjuvant zolbetuximab plus docetaxel, oxaliplatin, and S-1 (DOS) followed by adjuvant zolbetuximab/S-1 in patients with CLDN18.2-positive resectable gastric or gastroesophageal junction adenocarcinoma (NEOCLAUD).
TPS4250 Background: Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), has demonstrated significant su...
Clinicopathologic differences in early- vs. late-onset pancreatic cancer: A retrospective cohort study.
e16397 Background: Pancreatic cancer diagnosed in patients younger than 50 years has become increasingly common over the p...
Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: Updated efficacy and safety results from the phase II NeoTAPPL study.
600 Background: The KEYNOTE-522 and IMpassion031 trials established that adding immune checkpoint inhibitors to neoadjuvan...
Comparison of genomic landscapes at single cell resolution of pulmonary and salivary adenoid cystic carcinomas.
e18152 Background: Primary pulmonary adenoid cystic carcinomas (PACCs) are rare salivary-gland-like neoplasms associated w...
Transcriptomic validation of <i>ALK</i> fusions by RNA STEP with associated NaPi2b enrichment in lung adenocarcinoma.
e20763 Background: The RNA Salah Targeted Expression Panel (RNA STEP) is an exploratory clinical transcriptomic assay capa...
Implementation of a multidisciplinary committee within a national oncology society: An educational and quality improvement initiative.
e23033 Background: Multidisciplinary care is fundamental to improving quality, safety, and patient-centered outcomes in on...
Pathologic response in relation to total neoadjuvant therapy sequence, completion, and extra consolidation chemotherapy in locally advanced rectal cancer.
e15648 Background: Total neoadjuvant therapy (TNT) is widely used in locally advanced rectal cancer (LARC); however, the e...
Intracranial efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer with central nervous system involvement: A systematic review and proportional meta-analysis.
1053 Background: Central nervous system (CNS) metastases and leptomeningeal disease (LMD) are major drivers of morbidity a...
National burden and distribution of febrile neutropenia among hospitalizations with pancreatic cancer, 2016-2022.
e16409 Background: Febrile neutropenia (FN) is a potentially life-threatening complication of myelosuppressive chemotherap...